Posted by Michael Wonder on 19 Apr 2022
Enhertu granted priority review in the U.S. for patients with previously treated HER2 mutant metastatic non-small-cell lung cancer
19 April 2022 - Based on pivotal DESTINY-Lung01 results showing Daiichi Sankyo and AstraZeneca’s Enhertu demonstrated a 54.9% tumour response rate.
Daiichi Sankyo and AstraZeneca have received notification of acceptance of the supplemental biologics license application of Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients in the U.S. with unresectable or metastatic non-small-cell lung cancer whose tumours have a HER2 (ERBB2) mutation and who have received a prior systemic therapy.
